HCG Injection 5000iu

In assisted reproductive technologies such as in vitro fertilization embryo transfer, IVF-ET; In intrauterine insemination (IUI), HCG Injection is the core drug for inducing ovulation. Its mechanism of action is to simulate the LH peak before natural ovulation, triggering the rupture of mature follicles and releasing eggs. This process is crucial for the success of assisted reproductive technology, as it ensures that egg retrieval surgery is synchronized with egg maturation, improving embryo retrieval and transplantation success rates. This substance is usually injected with HCG 5000IU when ultrasound monitoring shows a dominant follicle diameter of 18-20 millimeters and serum estradiol levels reach an appropriate range. Egg retrieval surgery should be performed approximately 36 hours after injection to ensure that the eggs are in their optimal maturity state. Multiple studies have shown that HCG triggers (i.e. injecting HCG to induce ovulation) can significantly improve the success rate of assisted reproductive technologies. For example, in IVF-ET, egg retrieval 36 hours after HCG trigger can obtain a higher number of mature eggs, thereby improving embryo transfer rates and clinical pregnancy rates.

Luteal insufficiency refers to insufficient secretion of progesterone by the corpus luteum after ovulation, which may lead to poor development of the endometrium, affecting embryo implantation and early pregnancy maintenance. HCG Injection can stimulate progesterone secretion in the corpus luteum, support early pregnancy, and reduce the risk of miscarriage. Starting from the 15th to 17th day of the menstrual cycle (after ovulation), inject 1500-2500IU HCG intramuscularly every other day for 5 consecutive doses, or adjust the dosage according to the patient's response. Maintain the original dose until 7-10 weeks of pregnancy to ensure continued luteal function support during pregnancy. Multiple studies have shown that HCG supportive therapy can significantly improve pregnancy rates and reduce the risk of early miscarriage in patients with luteal insufficiency.

In recent years, studies have found that HCG not only acts on corpus luteum tissue, but also exists in tissues such as endometrium, blood vessels, and muscle layer. Intrauterine infusion of HCG can directly act on the local endometrium, improve endometrial receptivity, and increase the success rate of embryo implantation. Suitable for patients with thin endometrium and recurrent embryo implantation failure (RIF). 3-5 minutes or 1 day before embryo transfer, inject 500-1000IU HCG into the uterine cavity. Multiple studies have shown that intrauterine infusion of HCG can significantly improve clinical pregnancy rates and embryo implantation rates. For example, a meta-analysis showed that intrauterine infusion of HCG before embryo transfer significantly increased the HCG positivity rate and sustained pregnancy rate of fresh embryo transfer.

Oligozoospermia refers to a disease in which the number of sperm is below the normal range (usually considered sperm density<15 million/ml). This disease can be caused by various factors, including reproductive system infections, varicocele, endocrine disorders, etc. Among them, patients with oligospermia caused by endocrine abnormalities, especially those with low levels of gonadotropins, have a better response to HCG treatment. For oligospermia patients with low levels of gonadotropins, HCG can indirectly promote sperm production by increasing testosterone concentration. Testosterone is an important hormone for sperm production, and its elevated levels can stimulate the development of seminiferous tubules and sperm production.

Cryptorchidism refers to a disease in which the testicles fail to descend from the lower abdomen to the bottom of the scrotum according to the normal development process. This disease can lead to impaired fertility and increased risk of testicular malignancy. According to the different positions of the testicles, cryptorchidism can be divided into types such as intra-abdominal cryptorchidism, inguinal canal cryptorchidism, and scrotal entrance cryptorchidism. HCG can simulate hormonal changes during puberty, stimulate testicular cord contraction and testicular descent. For children under 2 years old with cryptorchidism, HCG treatment can promote testicular descent to the scrotum, avoiding future fertility impairment and increased risk of testicular malignancy.